Acne is a common chronic inflammatory skin disease and perceived as a self-limited disease in adolescence. The start of acne vulgaris differs within the age groups and it more prevalent during the onset of puberty. This can continue to be a problem as its prevalence remains high in adulthood. Acne vulgaris in the teenagers is leading to depression and diminishing the quality of life. The beginning of acne vulgaris is complex and incompletely understood. A variety of factors increase the risk for acne vulgaris, out of which the four main factors that are responsible for the active acne lesions are excessive sebum production, bacterial growth and colonization, sloughing of keratinocytes and inflammation and immune system response.According to an article published in British Medical Journal, almost 90% of the teenagers affected by acne and around 50% of them continue to experience symptoms as adults. In addition, it is noticed that by age of 40 years, 1% of men, and 5% of women still had lesions formed because of acne.
Acne vulgaris treatment market segmentation is done on basis of treatment and geography. The Treatment segment differentiated into therapeutics and other treatment. The therapeutic segment is further classified as Retinoid (Adapalene, Tazaroteen, Tretinoin and Isotretinoin), Antibiotics (Erythromycin and Clindamycin), Hormonal agents, combination medications, anti-inflammatory and other agents (Azelaic acid and Resorcinol).
Other treatment consists of laser and light therapy, cosmetic procedures and acne scar treatments. Based on the geography, the acne vulgaris market segmentation is North America, Europe, Asia Pacific, Latin America, and Rest of the World. North America dominates the market of acne vulgaris treatment; as acne is the most common disorder in the United States affecting 40 to 50 million population.
Browse full report on Acne Vulgaris Treatment Market –
Increasing awareness about the acne in the teenagers, rise in the disposable income has encouraged the consumers to purchase skin care products, unhealthy eating habits and sedentary lifestyle leading to the hormonal problems resulting in development of acne, high prevalence rate of acne and recent as well as upcoming treatments for acne are responsible to drive the acne vulgaris treatment market. The entry of the generics in the acne treatment drug market and the safety issues regarding the products were the factors responsible to hinder the growth of the market.
Some of the major key players in the acne vulgaris treatment market are Valeant Pharmaceutical International Inc. Galderma S.A., Allergan, Stiefel Laboratories, Inc. Bayer AG, Cipher, Hygeia Laboratories Inc. and Johnson & Johnson Private Limited.
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include
Middle East and Africa
This report provides comprehensive analysis of
Market growth drivers
Factors limiting market growth
Current market trends
Market projections for upcoming years
Request for brochure of this report –
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453